ArticleInternational journal of general medicine2025
Effect of Bdq-Containing Regimen and Molecular Detection of Bdq Resistance among Pre-XDR-TB Patients with Unfavorable Outcomes.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The objective of this study was to evaluate the efficacy of bedaquiline (Bdq)-containing regimens in pre-extensively drug-resistant tuberculosis (pre-XDR-TB) patients in Shenzhen, China, and to investigate the association between Bdq resistance and unfavorable outcomes. Methods: Data were collected from 84 pre-XDR-TB patients categorized into Bdq (n = 46) and non-Bdq (n = 38) groups. Individuals in the Bdq group were treated with Bdq alongside individualized background drugs. Commonly used drugs (>50% of patients) in both groups were linezolid (Lzd), clofazimine (Cfz), cycloserine (Cs) and pyrazinamide (Pza). Treatment outcomes were classified as cure, treatment completion, treatment failure, loss to follow-up, or death. Logistic regression analysis was conducted to determine independent predictors of treatment success using potential risk factors, including age, sex, body mass index (BMI), TB treatment history, and other factors. Whole-genome sequencing (WGS) was conducted on clinical isolates from 4 patients with unfavorable outcomes and 4 patients with favorable outcomes in the Bdq group. Results: Favorable treatment outcomes were observed in 89.13% (41/46) of the Bdq group and 52.63% (20/38) of the non-Bdq group (P = 0.0005). Univariate and multivariate analyses identified Bdq was an independent factor associated with treatment success (odds ratio [OR] = 11.572, 95% CI: 2.183-61.343, P = 0.004). WGS identified an atpE_Ala63Pro mutation conferring Bdq resistance in one patient with an unfavorable outcome. Additional resistance mutations included Rv0678_Arg156fs (Bdq and Cfz resistance) and rplC_Cys154Arg (Lzd resistance). Conclusion: Bdq-containing regimens significantly improved the treatment outcomes among pre-XDR-TB patients. The emergence of resistance mutations highlights the importance of routine drug resistance monitoring and rational drug use. Expanding access to Bdq and other novel drugs at affordable prices is vital for improving the success of pre-XDR-TB treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.